Prevention of Fluorouracil-induced Cardiotoxicity with Tetramethylpyrazine
-
摘要: 目的 探讨川芎嗪(TMP)对5-氟尿嘧啶(5-Fu)在食管癌化疗中出现的心脏毒性的防治作用。方法研究分为对照组和观察组，对照组单用化疗，观察组化疗同时使用川芎嗪。观察两组患者心电图及心肌酶谱等指标评价心脏毒性，并观察肿瘤缓解情况及其他不良反应。结果观察组和对照组心脏不良反应发生率分别为7.9%和1.4%，差异有统计学意义(P<0.05)；缓解率分别为55.6%和48.6%，差异无统计学意义(P＞0.05)。两组均有骨髓抑制和胃肠道反应，差异无统计学意义(P＞0.05)。结论川芎嗪可防治5-Fu引起的心脏毒性，对心脏的保护作用疗效确切。Abstract: Objective To investigate the efficacy of tetramethylpyrazine(TMP) to prevent 5-fluor ouracil(5-Fu)-associated cardiotoxicity during the chemotherapy of esophageal carcinoma. Methods Patients were divided into two groups in a random manner.Both groups were treated with FLP chemotherapy.The difference between the two groups is that the former(test group) was concomitantly treated with TMP,while the latter(control group) was not given TMP.Clinical manifestation,cardiac enzyme serum levels,and electrocardiogram were recorded to evaluate 5-Fu associated cardiotoxicity.Tumor objective response rate was also recorded.Data were analyzed statistically. Results The overall incidence of cardiotoxicity in control group with treatment of 5-Fu alone is 7.9%,whereas the value was only 1.4% in 5-Fu plus TMP group (P<0.05).There was no difference in tumor objective response rate between these two groups (P>0.05).Bone marrow suppression was observed in both groups,manifested mainly by leucopenia,decrease of hemoglobin and platelet.But the severity was mild to moderate.No difference was observed between the two groups(P>0.05).Side effects on gastrointestinal tract were also observed in both groups,manifested mainly by nausea and vomiting.There was no difference between the two groups (P>0.05). Conclusion TMP is effective in preventing cardiotoxicity induced by 5-Fu.
-
Key words:
- Tetramethylpyrazine /
- 5-Fluorouracil /
- Cardiotoxicity
-
-
[1] Conroy T,Yataghène Y,Etienne PL,et al.Phase Ⅱ randomised trial of chemoradiotherapy with FOLFOX4 orcisplatin plus fluorouracil in oesophageal cancer[J].Br J Cancer,2010,103(9):1349-55. [2] Tsavaris N,Kosmas C,Vadiaka M,et al.5-fluorouracil cardiotoxicity is a rare,dose and schedule-dependent adverse event:a prospective study[J].J Buon,2005,10(2):205-11. [3] Kosmas C,Kallistratos MS,Kopterides P,et al.Cardiotoxicity of fluoropyrimidines in differentschedules of administration:a prospective study[J].J Cancer Res Clin Oncol,2008,134(1):75-82. [4] Jensen SA,Sresen JB.Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil orcapecitabine[J].Cancer Chemother Pharmacol,2006,58(4):487-93. [5] Tsalic M,Bar-Sela G,Beny A,et al.Severe toxicity related to the 5-fluorouracil/leucovorincombination(the Mayo Clinic regimen):a prospective study in colorectal cancer patients[J].Am J ClinOncol,2003,26(1):103-6. [6] Alter P,Herzum M,Soufi M,et al.Cardiotoxicity of 5-fluorouracil[J].Cardiovasc Hematol AgentsMed Chem,2006,4(1):1-5. [7] Tsibiribi P,Descotes J,Lombard-Bohas C,et al.Cardiotoxicity of 5-fluorouracil in 1350 patientswith no prior history of heart disease[J].Bull Cancer,2006,93(3):E27-30. [8] Schber C,Papageorgiou E,Harstrick A,et al.Cardiotoxicity of 5-fluorouracil in combination withfolinic acid in patients with gastrointestinal cancer[J].Cancer,1993,72(7):2242-7.
计量
- 文章访问数: 2457
- HTML全文浏览量: 27
- PDF下载量: 702
下载:
